Capsule commentary on Efird et al., identifying the risks of anticoagulation in patients with substance abuse.
作者信息
Kirley Katherine
机构信息
NorthShore University HealthSystem, The University of Chicago Pritzker School of Medicine, Evanston, IL, 60201, USA,
出版信息
J Gen Intern Med. 2013 Oct;28(10):1351. doi: 10.1007/s11606-013-2486-1.
Abstract
摘要
相似文献
1
Capsule commentary on Efird et al., identifying the risks of anticoagulation in patients with substance abuse.关于埃菲德等人的胶囊评论，确定药物滥用患者抗凝治疗的风险。
J Gen Intern Med. 2013 Oct;28(10):1351. doi: 10.1007/s11606-013-2486-1.
2
Identifying the risks of anticoagulation in patients with substance abuse.识别滥用药物患者的抗凝风险。
J Gen Intern Med. 2013 Oct;28(10):1333-9. doi: 10.1007/s11606-013-2453-x. Epub 2013 Apr 26.
3
Letter by Hjemdahl et al regarding article, "Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial".
Circulation. 2013 Mar 19;127(11):e505. doi: 10.1161/CIRCULATIONAHA.112.135343.
4
Letter by David et al regarding article, "Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) Randomized Trial".
Circulation. 2013 Mar 19;127(11):e504. doi: 10.1161/CIRCULATIONAHA.112.133041.
5
The intersection of risk and benefit: is warfarin anticoagulation suitable for atrial fibrillation in patients on hemodialysis?
Chest. 2009 Oct;136(4):1128-1133. doi: 10.1378/chest.09-0730.
6
Letter by Feng et al regarding article, "Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control".冯等人就“阿司匹林、达比加群和华法林所致缺血性卒中和颅内出血：抗凝控制质量的影响”一文所写的信。
Stroke. 2015 Mar;46(3):e71. doi: 10.1161/STROKEAHA.114.008578. Epub 2015 Feb 3.
7
Does telehealth improve anticoagulation management in patient service centers (PSC)? A pilot project.远程医疗是否能改善患者服务中心（PSC）的抗凝管理？一项试点项目。
J Thromb Thrombolysis. 2020 Feb;49(2):316-320. doi: 10.1007/s11239-019-02031-4.
8
The risk of fetal loss associated with Warfarin anticoagulation.与华法林抗凝相关的胎儿丢失风险。
Int J Gynaecol Obstet. 2002 Sep;78(3):221-5. doi: 10.1016/s0020-7292(02)00186-8.
9
Risks related with withholding and resuming anticoagulation in patients with non-variceal upper gastrointestinal bleeding while on warfarin therapy.华法林治疗中伴有非静脉曲张性上消化道出血的患者在抗凝治疗时停药和重新开始抗凝的相关风险。
Int J Clin Pract. 2012 Jan;66(1):64-8. doi: 10.1111/j.1742-1241.2011.02827.x.
10
Management of intracranial bleeding in anticoagulated patients.抗凝患者颅内出血的管理。
Br J Hosp Med (Lond). 2009 Jun;70(6):336-8. doi: 10.12968/hmed.2009.70.6.336.
本文引用的文献
1
Identifying the risks of anticoagulation in patients with substance abuse.识别滥用药物患者的抗凝风险。
J Gen Intern Med. 2013 Oct;28(10):1333-9. doi: 10.1007/s11606-013-2453-x. Epub 2013 Apr 26.
2
National trends in oral anticoagulant use in the United States, 2007 to 2011.2007年至2011年美国口服抗凝剂使用的全国趋势。
Circ Cardiovasc Qual Outcomes. 2012 Sep 1;5(5):615-21. doi: 10.1161/CIRCOUTCOMES.112.967299. Epub 2012 Sep 4.
3
Scores to predict major bleeding risk during oral anticoagulation therapy: a prospective validation study.预测口服抗凝治疗期间大出血风险的评分：一项前瞻性验证研究。
Am J Med. 2012 Nov;125(11):1095-102. doi: 10.1016/j.amjmed.2012.04.005. Epub 2012 Aug 30.
Zotero 插件